12
Participants
Start Date
February 1, 2026
Primary Completion Date
February 1, 2029
Study Completion Date
May 1, 2029
CBG/CBD Oil
Participants will receive a commercially available high CBG/CBD hemp extract oil that also contains small amounts of cannabichromene (CBC). The product is formulated as a sublingual oil and administered twice daily. Participants will take 0.5 mL of the oil sublingually twice daily during the first week, followed by 1 mL sublingually twice daily for the remaining 11 weeks. The oil has a defined and independently verified cannabinoid and terpene profile and is marketed as a dietary supplement.
Penn State Cancer Institute, Hershey
Milton S. Hershey Medical Center
OTHER